Contraindications
The inadequate dimensions (too small) of the electrodes in use could provoke skin
reactions or bruises.
The device must not be used in presence of cancerous injuries in the area to be
treated. The stimulation should not be applied to infected, swollen or inflamed
areas and in case of rashes (phlebitis, thrombophlebitis, etc.).
It is absolutely forbidden to use MIO-CARE if the patient suffers from severe
arrythmia or has a pacemaker, suffers from epilepsy, heart-related pathologies,
phlebitis in place, thrombophlebitis, in feverish state, anxiety or serious illnesses,
abdominal or inguinal hernias or in case of severe injuries in the area to be treated
(except in case of medical prescription).
Do not use the device if the source of the pain is unknown or not diagnosed. Use
the device ONLY after having a diagnosis. In the event of injury, muscle stress or
any other health problem consult your doctor before using the device and only use
it under medical supervision.
Side effects
No significant side effects are known. In some cases of particularly sensitive
people, skin redness occurs at the electrodes after treatment: the redness
normally disappears few minutes after treatment. If the redness persists, consult
a doctor.
In some rare cases evening stimulation causes some difficulties in falling asleep. In
this case, suspend the treatment and consult a doctor.
Warnings
Treatment efficacy depends on the patients' selection by qualified persons. The
long-term effects of a chronic stimulation are unknown.
MIO-CARE has been designed and manufactured to be operated exclusively with
the internal, rechargeable batteries.
It is recommended:
•
to control position and meaning of all the labels on the equipment;
•
not to damage the connection cables to the electrodes and to avoid winding
the cables around the device;
•
to avoid the use of the device by persons who did not read carefully this
manual. Keep the device away from children, it contains small pieces that
could be swallowed;
•
not to wear metal objects during treatment;
IACER Srl
69
MNPG95